急性リンパ球/リンパ芽球性白血病 (ALL)治療法の世界市場:薬別(ハイパーCVADレジメン、リンカーレジメン、ヌクレオシド代謝阻害剤、標的薬物および免疫療法、CALGB 8811レジメン、およびオンカスパー)、種類別(小児および成人)...市場調査レポートについてご紹介

【英文タイトル】Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Drug (Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar), and Type (Pediatric and Adult): Global Opportunity Analysis and Industry Forecast, 2019–2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits to Stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porters five forces analysis

3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in the Incidences of Acute Lymphoblastic Leukemia
3.4.1.2. Rise in Number of New Product Approvals

3.4.2. Restraints

3.4.2.1. Patent Expiry of Blockbuster Drugs
3.4.2.2. Side effects of the treatment

3.4.3. Opportunity

3.4.3.1. Increase in number of Clinical Trials

CHAPTER 4: ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pediatric

4.2.1. Market size and forecast

4.3. Adult

4.3.1. Market size and forecast

CHAPTER 5: ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

5.1. Overvie

5.1.1. Market size and forecast

5.2. Hyper-CVAD regimen

5.2.1. Market size and forecast

5.3. Linker regimen

5.3.1. Market size and forecast

5.4. Nucleoside metabolic inhibitors (Clolar and Nelarabine)

5.4.1. Market size and forecast

5.5. Targeted drugs & immunotherapy

5.5.1. Market size and forecast

5.6. CALGB 8811 regimen

5.6.1. Market size and forecast

5.7. Oncaspar

5.7.1. Market size and forecast

CHAPTER 6: ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities

6.3. Europe

6.3.1. Key market trends and opportunities

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities

6.5. LAMEA

6.5.1. Key market trends and opportunities

CHAPTER 7: COMPANY PROFILES

7.1. AMGEN, INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BRISTOL-MYERS SQUIBB COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. ERYTECH PHARMA

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Key strategic moves and developments

7.4. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. NOVARTIS AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. PFIZER, INC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. RARE DISEASE THERAPEUTICS, INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. SANOFI

7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Product portfolio
7.8.4. Business performance

7.9. SPECTRUM PHARMACEUTICALS, INC

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments


【レポート販売概要】

■ タイトル:急性リンパ球/リンパ芽球性白血病 (ALL)治療法の世界市場:薬別(ハイパーCVADレジメン、リンカーレジメン、ヌクレオシド代謝阻害剤、標的薬物および免疫療法、CALGB 8811レジメン、およびオンカスパー)、種類別(小児および成人)
■ 英文:Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Drug (Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar), and Type (Pediatric and Adult): Global Opportunity Analysis and Industry Forecast, 2019–2026
■ 発行日:2019年6月30日
■ 調査会社:Allied Market Research
■ 商品コード:AMR9AG045
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。